OXFORD BIOMEDICA ANNUAL GENERAL MEETING

Oxford, UK - 09 May 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions were duly passed at its Annual General Meeting, held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business (as defined by the Company):

• Resolution 9: to empower the Directors to allot equity securities, pursuant to section 80 of the Companies Act 1985 (the "Act"), up to an aggregate nominal amount of £1,129,256;
• Resolution 10: to empower the Directors to allot equity securities for cash, pursuant to section 95 of the Act as if section 89(1) of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares; and
• Resolution 11: in addition to the authority contained in Resolution 10, to empower the Directors to allot equity securities for cash, pursuant to section 95 of the Act as if section 89(1) of the Act did not apply to any such allotment up to an aggregate amount representing 5 per cent of presently issued shares.

Certified copies of the document setting out the above resolutions passed at the 2008 AGM have been submitted to the UK Listing Authority and will shortly be made available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

The results of the proxy voting in advance of the meeting will be made available on the website and the Notice of 2008 AGM (giving the full text of each of the above resolutions) can be viewed by clicking here.

- ends -